Evidence map›Paper›PMID 35563346›Full record

ArticleInternational journal of molecular sciences2022

An In Silico Methodology That Facilitates Decision Making in the Engineering of Nanoscale Protein Materials.

Eloi Parladé, Eric Voltà-Durán, Olivia Cano-Garrido, Julieta M Sánchez, Ugutz Unzueta, Hèctor López-Laguna, Naroa Serna, Montserrat Cano, Manuel Rodríguez-Mariscal, Esther Vazquez and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Eloi ParladéCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), C/Monforte de Lemos 3-5, 28029 Madrid, Spain.
Eric Voltà-DuránCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), C/Monforte de Lemos 3-5, 28029 Madrid, Spain.ORCID 0000-0003-0017-8274
Olivia Cano-GarridoNanoligent S.L., Eureka Building, Av. de Can Doménech s/n, Campus de la UAB, 08193 Bellaterra, Spain.
Julieta M SánchezCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), C/Monforte de Lemos 3-5, 28029 Madrid, Spain.
Ugutz UnzuetaCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), C/Monforte de Lemos 3-5, 28029 Madrid, Spain.ORCID 0000-0001-5119-2266
Hèctor López-LagunaCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), C/Monforte de Lemos 3-5, 28029 Madrid, Spain.
Naroa SernaNanoligent S.L., Eureka Building, Av. de Can Doménech s/n, Campus de la UAB, 08193 Bellaterra, Spain.
Montserrat CanoNanoligent S.L., Eureka Building, Av. de Can Doménech s/n, Campus de la UAB, 08193 Bellaterra, Spain.
Manuel Rodríguez-MariscalNanoligent S.L., Eureka Building, Av. de Can Doménech s/n, Campus de la UAB, 08193 Bellaterra, Spain.
Esther VazquezCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), C/Monforte de Lemos 3-5, 28029 Madrid, Spain.ORCID 0000-0003-1052-0424
Antonio VillaverdeCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), C/Monforte de Lemos 3-5, 28029 Madrid, Spain.ORCID 0000-0002-2615-4521
Universitat Autònoma de Barcelona · ES

Funding

ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
NIGMS NIH HHS R01 GM129325
6 · The paper itself

Abstract

Under the need for new functional and biocompatible materials for biomedical applications, protein engineering allows the design of assemblable polypeptides, which, as convenient building blocks of supramolecular complexes, can be produced in recombinant cells by simple and scalable methodologies. However, the stability of such materials is often overlooked or disregarded, becoming a potential bottleneck in the development and viability of novel products. In this context, we propose a design strategy based on in silico tools to detect instability areas in protein materials and to facilitate the decision making in the rational mutagenesis aimed to increase their stability and solubility. As a case study, we demonstrate the potential of this methodology to improve the stability of a humanized scaffold protein (a domain of the human nidogen), with the ability to oligomerize into regular nanoparticles usable to deliver payload drugs to tumor cells. Several nidogen mutants suggested by the method showed important and measurable improvements in their structural stability while retaining the functionalities and production yields of the original protein. Then, we propose the procedure developed here as a cost-effective routine tool in the design and optimization of multimeric protein materials prior to any experimental testing.

Indexed as

NanoparticlesProteinsBiocompatible MaterialsDecision MakingHumansPeptidesProtein EngineeringBiocompatible MaterialsPeptidesProteinsmutagenesisnanomaterialsnanomedicineprotein stability

Identifiers

PMID35563346
PMCPMC9099527
OpenAlexW4225155974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.